Full Press Release Details
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR , Her2 , BRCA1 2 mutant Breast Cancer.
IDYA
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR , Her2 , BRCA1 2 mutant Breast Cancer
Key Takeaway: IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR , Her2 , BRCA1 2 mutant Breast Cancer